Anticancer combination therapy
US-2017088609-A1 · Mar 30, 2017 · US
Combination therapy for neoplasia treatment
US10377828B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10377828-B2 |
| Application number | US-201514946067-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 19, 2015 |
| Priority date | Mar 7, 2013 |
| Publication date | Aug 13, 2019 |
| Grant date | Aug 13, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treatment of castration resistant prostate cancer comprising administering a therapeutically effective amount of an antibody comprising a heavy chain of SEQ ID NO: 39 and a light chain of SEQ ID NO: 40 which binds to IGF ligands IGF-1 and IGF-2 and reduces or blocks binding of IGF ligands IGF-1 and IGF-2 to their receptor in a patient in need thereof, and additionally administering a therapeutically effective amount of enzalutamide in combination with the antibody. 2. The method of claim 1 , wherein the enzalutamide is administered to the patient within seven days before or after administration of the antibody.
Assignees
Inventors
Classifications
- C07K16/2863Primary
against receptors for growth factors, growth regulators · CPC title
against growth factors {; against growth regulators} · CPC title
Antineoplastic agents · CPC title
of the prostate · CPC title
of the pancreatic hormones · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10377828B2 cover?
- The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).